Novo Nordisk - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
NVO
Novo Nordisk is a global healthcare company headquartered in Denmark, founded in 1923. The company specializes in medicines and therapies for diabetes and other serious chronic diseases, with a broad focus on long-term care and disease management. It operates internationally, developing treatments across disease areas including obesity and metabolic disorders, and emphasizes sustainable business practices and patient-centric care.
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
5 FDA Decisions to Watch in the First Quarter of 2026
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Trump's Obesity Drug Plan for Medicare Would Cost Insurers Billions
Biotech in 2025: A Retrospective
Lilly’s Obesity Pill Approval Kicks Off New Front in Weight-Loss Drug Wars
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
Eli Lilly’s Retatrutide Targets Novo Nordisk’s GLP‑1 Stronghold with 28.7% Weight Loss Data
Vercel COO Discusses How AI Will Bolster Human Interactions in Sales
Qualcomm Downgraded, Rivian Upgraded: Wall Street's Top Analyst Calls
The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
3 Trends Shaping the GLP-1 Landscape
Madrigal Eyes Combination MASH Therapy with Pfizer Deal
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
STAT+: Novo Nordisk Strikes Deal with U.S. Startup to Develop Oral Obesity, Diabetes Drugs
WHO Foundation, Novo Nordisk Collaborate on Childhood Obesity Prevention in India
New CagriSema Data Show Improvement over Semaglutide
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Office CMBS Delinquency Rate Spikes to Record 12.3%, Much Worse than Financial Crisis Meltdown Peak
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Trump Administration Sets up to 100% Tariffs on some Imported Drugs, with Many Companies Exempt
Labiotech’s 15 Biopharma Companies to Watch in 2026
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Feds Invest $79 Million in Aspect Biosystems to Develop 3D-Printed Tissue Treatment
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Generic GLP-1s Are Coming, but Americans Don’t Want to Wait
Strategy Pivot Hits GoodRx
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Aspect Biosystems and Novo Nordisk – Enter New Phase of Partnership to Develop Curative Medicines for Diabetes
GLP-1 Drugs Linked to Pancreatitis, Gallbladder Problems
Novo Nordisk Plans €432m Investment in Irish GLP-1 Plant
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
News Wrap: Johnson, Thune Agree on Path to Fund DHS Through September
Health Equity & Access Weekly Roundup: February 20, 2026
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
NHS to Offer Wegovy to Over 1 Million Heart Patients to Cut Cardiovascular Risk
Key Takeaways From AACE’s 2026 Type 2 Diabetes Algorithm
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
CMS's Medicare Price Negotiations Start Round Three
